Clozapine-Induced Myocarditis: Is Mandatory Monitoring Warranted for Its Early Recognition? | Zendy

Tariq Munshi | Zendy; D. Volochniouk | Zendy; Tariq Hassan | Zendy; Nadia Mazhar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clozapine-Induced Myocarditis: Is Mandatory Monitoring Warranted for Its Early Recognition?

Author(s) -

Tariq Munshi,

D. Volochniouk,

Tariq Hassan,

Nadia Mazhar

Publication year - 2014

Publication title -

case reports in psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.17

H-Index - 4

eISSN - 2090-682X

pISSN - 2090-6838

DOI - 10.1155/2014/513108

Subject(s) - clozapine , medicine , myocarditis , schizophrenia (object oriented programming) , antipsychotic , atypical antipsychotic , psychosis , psychiatry , intensive care medicine , pediatrics

Clozapine is an atypical antipsychotic used for treatment resistant schizophrenia. Its potential to induce agranulocytosis is well known but it can also cause myocarditis. Clozapine is the only antipsychotic known to induce this side effect, typically early in the treatment, and literature is scarce on this condition. We are presenting a case report of a 21-year-old schizophrenic male who developed myocarditis within 3 weeks of starting on clozapine for his treatment resistant psychosis. We then aim to review some of the available literature and raise awareness among physicians as this condition can potentially be fatal if not detected early.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research